RoSA Radiopharmaceuticals Market to 2032

Overview

The RoSA Radiopharmaceuticals Market is expected to reach a 64.82 USD Billion by 2032 and is projected to grow at a CAGR of 5.88% from 2025 to 2032.

Revenue, 2024 (USD Billion)
47.00
Forecast, 2032 (USD Billion)
64.82
CAGR, 2024 - 2032
5.88%
Report Coverage
RoSA

RoSA Radiopharmaceuticals Market 2018-2032 USD Billion

RoSA Radiopharmaceuticals Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 47.00 USD Billion
  • Projected Market Size (2032): 64.82 USD Billion
  • CAGR (2025-2032): 5.88%

Key Findings of RoSA Radiopharmaceuticals Market

  • The RoSA Radiopharmaceuticals Market was valued at 64.82 USD Billion in 2024.
  • The RoSA Radiopharmaceuticals Market is likely to grow at a CAGR of 5.88% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Nuclear Reactors in By Source Segment accounted for the largest share of the market with a revenue of 28.47 USD Billion
  • The fastest growing segment Hospitals in End User Segment grew Fastest with a CAGR of 6.54% during the forecast period from 2024 to 2032.

RoSA Radiopharmaceuticals Market Scope

RoSA Radiopharmaceuticals Market Segmentation & Scope
By Application
  • Therapeutic
  • Diagnostic
By Source
  • Cyclotrons
  • Nuclear Reactors
End User
  • Others
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Diagnostic Centers
  • Hospitals
By Type
  • Therapeutic Radiopharmaceuticals
  • Diagnostic Radiopharmaceuticals

RoSA Radiopharmaceuticals Market Data Coverage Insights

Study Period 2024-2032
Base Year 2021
Unit Revenue in USD Billion
Market Value in 2024 47.00 USD Billion
Market Value in 2032 64.82 USD Billion
CAGR (2025-2032) 5.88%
Historic Data 2016-2023
Market Segments Covered By Application,By Source,End User,By Type

Regional Insights:

  • Leading Market (2024-2032): RoSA, leading in terms of revenue 47.00 USD Billion in 2024
    • Key Country: RoSA, leading in terms of revenue with value of 47.00 USD Billion in 2024.

Segments and Scope

  • RoSA Radiopharmaceuticals Market to 2032, By By Application
    • Diagnostic is the largest segment in RoSA Radiopharmaceuticals Market to 2032 with a revenue of 25.65 USD Billion in the year 2024.
    • Diagnostic is the Fastest growing segment in RoSA Radiopharmaceuticals Market to 2032 with a Growth rate of 6.38 % in forecast period 2025-2032.
  • RoSA Radiopharmaceuticals Market to 2032, By By Source
    • Nuclear Reactors is the largest segment in RoSA Radiopharmaceuticals Market to 2032 with a revenue of 28.47 USD Billion in the year 2024.
    • Nuclear Reactors is the Fastest growing segment in RoSA Radiopharmaceuticals Market to 2032 with a Growth rate of 6.27 % in forecast period 2025-2032.
  • RoSA Radiopharmaceuticals Market to 2032, By End User
    • Hospitals is the largest segment in RoSA Radiopharmaceuticals Market to 2032 with a revenue of 18.65 USD Billion in the year 2024.
    • Hospitals is the Fastest growing segment in RoSA Radiopharmaceuticals Market to 2032 with a Growth rate of 6.54 % in forecast period 2025-2032.
  • RoSA Radiopharmaceuticals Market to 2032, By By Type
    • Diagnostic Radiopharmaceuticals is the largest segment in RoSA Radiopharmaceuticals Market to 2032 with a revenue of 26.99 USD Billion in the year 2024.
    • Diagnostic Radiopharmaceuticals is the Fastest growing segment in RoSA Radiopharmaceuticals Market to 2032 with a Growth rate of 6.34 % in forecast period 2025-2032.

RoSA Radiopharmaceuticals Market Company Share Analysis

 
Company Name Company Share Analysis
Cardinal Health
Advanced Accelerator Applications, A Novartis Company
GE HealthCare
Lantheus
Curium and its affiliates
RoSA Radiopharmaceuticals Market Company Share Analysis

RoSA Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Billion

RoSA Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Billion

RoSA Radiopharmaceuticals Market Company Profiling

RoSA Radiopharmaceuticals Market Company Profiling
Frequently Asked Questions
The RoSA Radiopharmaceuticals Market is segmented based on Segmentation By Application,By Source,End User,By Type.
RoSA Radiopharmaceuticals Market was valued at USD 47.00(Revenue in USD Billion) in 2021.
RoSA Radiopharmaceuticals Market is projected to grow at a CAGR of 5.88% during the forecast period of 2024 to 2032.
The Nuclear Reactors segment is expected to dominate the RoSA Radiopharmaceuticals Market, holding a largest market share of 28.47 USD Billion in 2024

RoSA Radiopharmaceuticals Market Scope

RoSA Radiopharmaceuticals Market Segmentation & Scope
By Application
  • Therapeutic
  • Diagnostic
By Source
  • Cyclotrons
  • Nuclear Reactors
End User
  • Others
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Diagnostic Centers
  • Hospitals
By Type
  • Therapeutic Radiopharmaceuticals
  • Diagnostic Radiopharmaceuticals
Frequently Asked Questions
The RoSA Radiopharmaceuticals Market is segmented based on Segmentation By Application,By Source,End User,By Type.
RoSA Radiopharmaceuticals Market was valued at USD 47.00(Revenue in USD Billion) in 2021.
RoSA Radiopharmaceuticals Market is projected to grow at a CAGR of 5.88% during the forecast period of 2024 to 2032.
The estimated market value of the RoSA Radiopharmaceuticals Market for final year is USD 64.82 (USD Billion).

RoSA Radiopharmaceuticals Market Company Profiling

RoSA Radiopharmaceuticals Market Company Profiling
Frequently Asked Questions
The RoSA Radiopharmaceuticals Market is segmented based on Segmentation By Application,By Source,End User,By Type.
RoSA Radiopharmaceuticals Market was valued at USD 47.00(Revenue in USD Billion) in 2021.
RoSA Radiopharmaceuticals Market is projected to grow at a CAGR of 5.88% during the forecast period of 2024 to 2032.
The estimated market value of the RoSA Radiopharmaceuticals Market for final year is USD 64.82 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.